![Dalton Smart](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Dalton Smart
Director Ejecutivo en HARPOON THERAPEUTICS, INC. .
Fortuna: 555 891 $ al 31/05/2024
Cargos activos de Dalton Smart
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
MERCK & CO., INC. | Comptroller/Controller/Auditor | 04/12/2023 | - |
Corporate Officer/Principal | 01/09/2023 | 04/12/2023 | |
HARPOON THERAPEUTICS, INC. | Director Ejecutivo | - | - |
ACCELERON PHARMA INC. | Director/Miembro de la Junta | - | - |
Presidente | - | - | |
Junior Achievement of New Jersey, Inc. | Director/Miembro de la Junta | - | - |
Historial de carrera de Dalton Smart
Estadísticas
Internacional
Estados Unidos | 5 |
Operativa
Director/Board Member | 2 |
Comptroller/Controller/Auditor | 1 |
Corporate Officer/Principal | 1 |
Sectorial
Health Technology | 4 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
MERCK & CO., INC. | Health Technology |
Empresas privadas | 3 |
---|---|
Junior Achievement of New Jersey, Inc. | |
Harpoon Therapeutics, Inc.
![]() Harpoon Therapeutics, Inc. BiotechnologyHealth Technology Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which engages in the development of antibodies. It focuses on the research of novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. The firm utilizes its proprietary Tri-specific T cell Activating Construct platform to create a pipeline of novel TriTACs for the treatment of solid tumors and hematologic malignancies. The company was founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA. | Health Technology |
Acceleron Pharma, Inc.
![]() Acceleron Pharma, Inc. BiotechnologyHealth Technology Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis on June 13, 2003 and is headquartered in Rahway, NJ. | Health Technology |
- Bolsa de valores
- Insiders
- Dalton Smart
- Experiencia